Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms GR 1803, GR-1803, GR1803 |
Target |
Action modulators, stimulants |
Mechanism BCMA modulators(B-cell maturation protein modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Extramedullary Plasmacytoma | Phase 2 | China | 24 Apr 2025 | |
Relapse multiple myeloma | Phase 2 | China | 24 Apr 2025 | |
Multiple Myeloma | Phase 2 | China | 11 Aug 2024 |
Phase 1 | 50 | (All pts) | nswrcsfwyv(raqwnvrywv) = esjcboxlab jytwpdsonh (coljlbyxby ) View more | Positive | 14 May 2024 | ||
(180ug/kg) | pannqfddpb(masqvqderq) = izhencjmwz xmixnvxnwd (ndiyhcvdfz ) |